Eli Lilly Zepbound Coverage +5.2% as CVS Restores Access
Can restored CVS access turn Eli Lilly Zepbound Coverage into the next big advantage in the obesity drug war? Maik Kemper Editor in Chief “Collaboration with pharmaceutical companies…
Novo Nordisk FDA Compounding +4.8% Surge Shakes GLP‑1 Rivals
Will the Novo Nordisk FDA Compounding crackdown finally shut down GLP‑1 copycats and supercharge the branded obesity drug boom? Maik Kemper Editor in Chief When FDA‑approved drugs are…
Hims & Hers peptide regulation: +10.5% rally tests FDA bet
Is the latest FDA shift on peptides turning Hims & Hers into a long-term growth story or just fueling a speculative spike? Maik Kemper Editor in Chief Conclusion…
Novo Nordisk AI Partnership Boom: Can It Close the Obesity Gap?
Can the Novo Nordisk AI Partnership with OpenAI turn a battered obesity champion into the next big winner of the healthcare AI boom? Maik Kemper Editor in Chief…
Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock
Can Eli Lilly Retatrutide’s powerful Phase 3 diabetes data reignite confidence in the GLP-1 boom despite rising competitive and pricing fears? Maik Kemper Editor in Chief With triple…
Hims & Hers insider transactions Warning as GLP-1 bets grow
Are Hims & Hers insider transactions hinting at caution just as the company doubles down on its high-stakes GLP-1 obesity strategy? Maik Kemper Editor-in-Chief Conclusion In conclusion, the…
Novo Nordisk Hims partnership Boom: GLP‑1 market power shift
Can the Novo Nordisk Hims partnership turn a legal fight over compounded GLP‑1s into a powerful new growth channel for both sides? How does the Novo Nordisk Hims…